Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 462-466

  Nishank, Sudhansu Sekhar ^a   Singh, Mendi Prema Shyam Sunder ^a   Yadav, Rajiv ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Genes; Sickle cell disease; Thrombophilic mutation; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; PROTHROMBIN;

ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; INDIA; INFANT; MAJOR CLINICAL STUDY; NEWBORN; ONSET AGE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SICKLE CELL ANEMIA;

GENES; SICKLE CELL DISEASE; THROMBOPHILIC MUTATION; THROMBOSIS;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTITHROMBIN III; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FACTOR V; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PEPTIDE HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN C; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 84885927429     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12190     Document Type: Article

References (16)

1. Weatherall DJ. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001;79:704-12.
2. Ataga KI, Cappellini MD, Rachmilewitz EA. β-thalassaemia and sickle cell anemia as paradigms of hypercoagulability. Br J Hematol 2007;139:3-13.
3. Gupta RB. Regional Medical Research Centre for Tribals UPDATE. ICMR, News Bulletin 2006;3:1-3.
4. Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A. Thrombophilic mutations among southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden. J Thromb Thrombolysis 2008;25:288-92.
5. Andade FL, Annichino-Bizzacchi JM, Saad STO, Costa FF, Arruda VR. Prothrombin Mutant, Factor V Leiden and thermolabile variants of Methylene tetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol 1998;59:46-50.
6. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, Stryhorn D, Hinderliter A, Key NS. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One 2012;7: e29786 p1-9.
7. Helley D, Besmond C, Ducroc R, da Silva F, Guillin MC, Bezeaud A, Elion J. Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease. Hum Genet 1997;100:245-8.
8. Moreira NF, Lourenco DM, Noguti MAE, Morelli VM, Gil ICP, Beltaro ACS, Figueiredo MS. The clinical impact of MTHFR polymorphism on vascular complications of sickle cell disease. Brazilian J Med Res 2006;39:1291-5.
9. Wright JG, Cooper P, Malia RG, Kulozik AE, Vetter B, Thomas P, Preston FE, Serjeant GR. Activated protein C resistance in homozygous sickle cell anemia. Br J Haematol 1997;96:854-6.
10. Fawaz NA, Bashawery L, Al-Sheikh I, Qatari A, Al-Othman S, Almawi WY. Factor V- Leiden, Prothrombin G20210A and MTHFR C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia. Am J Haematol 2004;76:307-9.
11. Couto FD, Boas WV, Lyra I, Zanette A, Dupuit MF, Almeida MN, Reis MG. Goncalves MS A C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism and G20210A mutation in the prothrombin gene of sickle cell anemia patients from Northeast Brazil. Hemoglobin 2004;28:237-41.
12. Hatzlhofer BL, Bezerra MA, Santos MN, Albuquerque DM, Freitas EM, Costa FF, Araujo AS, Muniz MT. MTHFR polymorphic variant C677T is associated to vascular complications in sickle-cell disease. Genet Test Mol Biomarkers 2012;16:1038-43.
13. Ahmed RPH, Gupta PK, Kannan M, Choudhry VP, Saxena R. Factor V Leiden-the commonest molecular defect in arterial and venous thrombophilia in India. Thromb Res 2003;110:19-21.
14. Rahimi Z, Parsian A, Sickle cell disease and venous thromboembolism. Mediterr J Hematol Infect Dis 2011;3:e2011024, doi:10.4084/MJHID.2011.024.
15. Gouin-Thibault I, Arkam R, Nassiri S, et al. markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thomb Hemost 2002;107:7-11.
16. Federici C, Gianetti J, Andreassi MG. Genomic medicine and thrombotic risk: who, when, how and why? Int J Cardio 2006;106:3-9.